GlassScriptPhysician profile
Jackie L Evans
NPI 1588657860
$10,255.33
in general payments reported to CMS, 2019-2025
52 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $884 · 2021: $978 · 2022: $1,967 · 2023: $1,950 · 2024: $1,966 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,373.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,645.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,542.32 | 2019-2025 | |
| Lilly USA, LLC | $1,056.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $635.73 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $486.87 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $450.97 | 2022-2025 | |
| Glaxosmithkline, LLC. | $418.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.44 | 2019-2025 | Jardiance |
| Pfizer INC. | $303.98 | 2019-2025 | |
| Astellas Pharma US INC | $265.88 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $238.37 | 2020-2023 | |
| Exact Sciences Corporation | $228.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $197.49 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $182.15 | 2019-2023 | Qelbree |
| Nestle Healthcare Nutrition INC. | $171.07 | 2020-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.